LAURIE REEVES: Open Payments
NPI 1942510698 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 40 payments from 20 companies in 2025. Trend: 2023 $1,178 · 2024 $768 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 12 | $181 |
| SHIELD THERAPEUTICS INC | 1 | $118 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Vanda Pharmaceuticals Inc. | 2 | $69 |
| Novo Nordisk Inc | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| ABBVIE INC. | 2 | $40 |
| GlaxoSmithKline, LLC. | 1 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
Products named: ACCRUFER, Fintepla, Briviact, FANAPT, AUSTEDO XR, REXULTI, Auvelity, EMBLAVEO.
Industry payments across CA — which companies pay providers there.
